Tebanicline
CAS No. 198283-73-7
Tebanicline ( —— )
Catalog No. M17413 CAS No. 198283-73-7
Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 50 | In Stock |
|
5MG | 90 | In Stock |
|
10MG | 141 | In Stock |
|
25MG | 295 | In Stock |
|
50MG | 405 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTebanicline
-
NoteResearch use only, not for human use.
-
Brief DescriptionTebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.
-
DescriptionTebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. Tebanicline is an effective synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects. Like epibatidine, Tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPLK
-
RecptornAChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number198283-73-7
-
Formula Weight198.65
-
Molecular FormulaC9H11ClN2O
-
Purity98%
-
Solubility——
-
SMILESC1CN[C@H]1COc1cnc(cc1)Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hayashi T, et al.Neurosci Lett. 2016 Dec 7;638:46-50.
molnova catalog
related products
-
GSK-461364
A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
-
CFI-400945
CFI-400945 is an potent, selective and orally active inhibitor of?polo-like kinase 4(PLK4; Ki value of 0.26 nM).
-
CFI-400437 dihydroch...
CFI-400437 is a selective and potent polo-like kinase 4 (PLK4) inhibitor.